• Ninja Blocks Kickstarter and the newly GPL-licensed SixthSense wearable AR platform were highlighted as concrete, low-cost, open-source hardware examples for building distributed sensing and augmented-reality labs at home.  

• A large trove of DIY-neuroscience links was circulated, including the 2008 Whole Brain Emulation Roadmap, invasive BCI papers, and optogenetics protocols, framing the channel as a living bibliography for open brain–computer-interface research.  

• Participants argued that gradual, region-by-region neural prosthesis (starting with Ted Berger’s artificial hippocampus) is a more practical and philosophically acceptable route to life-extension than destructive whole-brain scanning/uploading, explicitly prioritizing continuity of consciousness over “copy” debates.  

• EEG was dismissed as inadequate; the group asked whether high-density 256×256 electrode grids or Moore’s-law scaling in channel counts could soon provide the resolution needed for serious neural interfacing.  

• Offshore experimentation (China, India, Thailand, Russia) was discussed as a regulatory workaround for stem-cell, gene-therapy, and longevity trials, with China noted for both large-scale human studies and organ-harvest controversies.  

• Gene therapy is experiencing a revival via safer viral vectors (hemophilia, blindness trials), but funding remains scarce for general life-extension applications beyond single-disease targets.  

• Mouse studies showing cognitive rejuvenation via young-blood transfusion were shared, alongside ideas to isolate active factors and commercialize night-time “artificial blood” kits, potentially monetized through the Mprize longevity incentive structure.  

• Stee|’s nanoscale 3-D inkjet printing project for ceramics, PZT, metals, and biomaterials was presented as a near-term tool for rapid RF prototyping and a future funding vehicle for transhumanist R&D through angel investing and consulting.  

• Regulatory-arbitrage concepts included medical-tourism insurance plans, floating pharma-cruise ships in international waters, and pooled micro-angel networks to bypass accredited-investor rules and channel capital into high-risk longevity research.